Study links GLP-1 drugs to lower breast cancer risk

June 06, 2026

Reported by AI

Women taking GLP-1 medications such as Ozempic and Wegovy showed about 30 percent lower odds of developing breast cancer in a large observational study.

Researchers reviewed electronic health records from more than 111,000 women aged 45 to 80 with a body mass index of 25 or higher who underwent breast imaging at Penn Medicine between January 2022 and June 2025. Those prescribed GLP-1 drugs had 35.1 percent lower odds of breast cancer in the full group and 30.5 percent lower odds in a matched analysis. The findings were presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in JCO Oncology Practice. Elizabeth McDonald, a professor at the University of Pennsylvania Perelman School of Medicine, noted that the study was observational and does not prove causation. McDonald and colleagues plan to launch clinical trials to test whether GLP-1 drugs can help prevent breast cancer in high-risk women. The medications affect pathways linked to cancer development, though weight loss may also contribute to the observed benefit.

Realistic illustration contrasting social stigma: neutral for overweight, positive for exercise weight loss, negative for Ozempic users.

Study finds people who use Ozempic-like drugs for weight loss face added stigma

May 05, 2026 Reported by AI Image generated by AI Fact checked

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

Study links Ozempic to lower depression and anxiety risks

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

May 21, 2026 Reported by AI Fact checked

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

Health

Semaglutide shows strong weight loss results for adults over 65

Health

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

Technology

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

Teddi Mellencamp sought weight-loss meds amid stage 4 cancer battle

Teddi Mellencamp, the Real Housewives of Beverly Hills alum, spilled on her podcast that she begged her doctor for GLP-1 weight-loss drugs while battling cancer. She gained weight from steroids but got shut down. Joking about the irony, she quipped about living her best life without the meds.

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

April 01, 2026 Reported by AI

The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Researchers at Vanderbilt Health discovered that both popular weight loss drugs and bariatric surgery significantly reduce fat mass while causing modest losses in fat-free mass, including muscle, in patients with obesity. The findings, based on over 3,000 patients, show improvements in overall body composition over 24 months. Maintaining this balance is crucial for long-term health, the study emphasizes.

June 05, 2026 14:44